Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SmofKabiven Peripheral is a sterile, non-pyrogenic, three-chamber bag system for parenteral nutrition, developed by Fresenius Kabi. It contains a combination of amino acids, electrolytes, dextrose, and a unique four-oil lipid emulsion known as SMOFlipid, which comprises soybean oil, medium-chain triglycerides, olive oil, and fish oil. The Peripheral version is specifically formulated with a lower osmolarity (approximately 850 mOsm/L) compared to the central venous version, allowing it to be safely administered through a peripheral vein. This formulation is designed to provide balanced nutritional support, including essential omega-3 and omega-6 fatty acids, to adult patients for whom oral or enteral nutrition is impossible, insufficient, or contraindicated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SmofKabiven Peripheral.